SAB Biotherapeutics (SABS) Net Cash Flow (2020 - 2026)
SAB Biotherapeutics (SABS) posted Net Cash Flow of $10.0 million for Q1 2026, up 154.0% on a QoQ basis from -$18.5 million in Q4 2025, and up 403.09% year-over-year from $2.0 million in Q1 2025.
SAB Biotherapeutics (SABS) Net Cash Flow (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $10.0 million for Q1 2026.
- Quarterly Net Cash Flow rose 403.09% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (up 283.87% YoY) and the FY2025 annual result came in at $1.8 million, up 103.83% from the prior year.
- Net Cash Flow was $10.0 million for Q1 2026 at SAB Biotherapeutics, up from -$18.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $54.1 million in Q4 2023 and bottomed at -$42.5 million in Q1 2024.
- A 5-year average of -$1.1 million and a median of -$3.3 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 706.03% — and 2025, when it tumbled 119310.81%.
- SAB Biotherapeutics' Net Cash Flow stood at $6.7 million in 2022, then surged by 706.03% to $54.1 million in 2023, then plunged by 99.97% to $15539.0 in 2024, then tumbled by 119310.81% to -$18.5 million in 2025, then surged by 154.0% to $10.0 million in 2026.
- Business Quant data shows SABS's Net Cash Flow at $10.0 million in Q1 2026, -$18.5 million in Q4 2025, and $25.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.00 Mn |
| Mar 31, 2026 | 10.00 Mn |
| Dec 31, 2025 | -18.52 Mn |
| Dec 31, 2025 | -18.52 Mn |
| Sep 30, 2025 | 25.77 Mn |
| Sep 30, 2025 | 25.77 Mn |
| Jun 30, 2025 | -2.13 Mn |
| Jun 30, 2025 | -2.13 Mn |
| Mar 31, 2025 | -3.30 Mn |
| Mar 31, 2025 | -3.30 Mn |
| Dec 31, 2024 | 15,539.00 |
| Dec 31, 2024 | 15,539.00 |
| Sep 30, 2024 | -8.12 Mn |
| Sep 30, 2024 | -8.12 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Mar 31, 2024 | -42.50 Mn |
| Mar 31, 2024 | -42.50 Mn |
| Dec 31, 2023 | 54.12 Mn |
| Dec 31, 2023 | 54.12 Mn |